Sodium Valproate & Valproic Acid
Therapeutic Class: Drugs of Nervous System (Primary anti-epileptic drugs)
Indications:
Sodium Valproate & Valproic Acid is indicated for the treatment of all types of epilepsy, e.g. Partial seizures, Absence seizures (petit mal), Generalized tonic-clonic seizures (grand mal), Myoclonic seizures, Atonic seizures, Mixed seizures that include absence attack, Prophylaxis of febrile convulsion, Prophylaxis of post-traumatic epilepsy. It is also indicated in the treatment of bipolar disorder & prophylaxis of migraine.
Presentation:
200 tablet: Each enteric-coated controlled release tablet contains Sodium Valproate BP 133.2 mg & Valproic acid BP 58 mg equivalent to Sodium Valproate 200 mg.
300 tablet: Each enteric-coated controlled release tablet contains Sodium Valproate BP 199.8 mg & Valproic acid BP 87 mg equivalent to Sodium Valproate 300 mg.
500 tablet: Each enteric-coated controlled release tablet contains Sodium Valproate BP 333 mg & Valproic acid BP 145 mg equivalent to Sodium Valproate 500 mg.
Description:
Sodium Valproate & Valproic Acid, the active ingredient of Sodium Valproate & Valproic Acid is endowed with anti-epileptic activity against a variety of seizures. The mechanism by which Sodium Valproate exerts its anti-epileptic effects has not been established. However, it has been suggested that its activity is related to increased brain levels of gamma-aminobutyric acid (GABA).
Dosage & Administration:
Sodium Valproate & Valproic Acid is a prolonged-release formulation of sodium Valproate, thus Sodium Valproate & Valproic Acid may be given once or twice daily.
Epilepsy: Adults -Initially 600 mg daily given in 2 divided doses, preferably after food, increasing by 200 mg/day at 3-day intervals to a maximum of 2.5 g daily in divided doses until control of seizure is achieved. The usual maintenance dose is 1-2 g daily (20-30 mg/kg daily).
Children Initially 20 mg/kg daily in divided doses, may be increased (up to 20 kg) provided plasma concentrations monitored (above 40 mg/kg daily also monitor clinical chemistry and haematological parameters).
Children Initially 400 mg daily in divided doses increased until control (0ver 20 kg) (usually in the range of 20-30 mg/kg daily); Maximum 35 mg/kg daily.
Febrile convulsion20-30 mg/kg/day in 3 divided doses.
Bipolar disorder initially 20-30 mg/kg/day in 2-3 divided doses; adjust dosage in 3-5 days. The maintenance dosage is 1000-2000 mg/day. Prophylaxis of migraine 300 mg twice daily, although some may require 1000 mg daily.
Side Effects:
The most common side effects are anorexia, nausea and vomiting. However, these side effects are minimized with the use of enteric-coated tablets. Effects on the CNS include sedation, ataxia and tremor. These symptoms occur infrequently and usually respond to a decrease in doses. Rash, alopecia and stimulation of appetite have been observed occasionally. Sodium Valproate has several effects on the hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. Rarely fulminate hepatitis that may be fatal may develop. Children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are especially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of Sodium Valproate.
Precautions:
Liver functions should be monitored before therapy and during the first 6 months especially in patients most at risk, No undue potential for bleeding before starting and before major surgery must be ensured, Care should be taken in renal impairment, pregnancy, breast-feeding and systemic lupus erythematosus. Sodium Valproate is partially eliminated in the urine as a ketone metabolite, which may lead to a false interpretation of the urine ketone test. Sudden withdrawal of therapy should be avoided.
Use in Pregnancy & Lactation:
Sodium Valproate crosses the placenta and in humans, exposure to valproate in the first trimester has been associated with neural tube defects such as anencephaly and spina bifida in newborn. Pregnant women treated with Sodium Valproate & Valproic Acid should be offered to estimate serum a-fetoprotein. Sodium Valproate & Valproic Acid is excreted in breast milk. However, breastfeeding by a mother taking Sodium Valproate & Valproic Acid probably causes no risk to the child.
Interaction:
Sodium Valproate appears to act as a non-specific inhibitor of drug metabolism. Drugs to which it interacts most significantly are Phenobarbital, Phenytoin, Warfarin, Aspirin etc.
Storage:
Store in a cool and dry place, below 30 °C and keep away from light.
Sodium Valproate & Valproic Acid is indicated for the treatment of all types of epilepsy, e.g. Partial seizures, Absence seizures (petit mal), Generalized tonic-clonic seizures (grand mal), Myoclonic seizures, Atonic seizures, Mixed seizures that include absence attack, Prophylaxis of febrile convulsion, Prophylaxis of post-traumatic epilepsy. It is also indicated in the treatment of bipolar disorder & prophylaxis of migraine.
Presentation:
200 tablet: Each enteric-coated controlled release tablet contains Sodium Valproate BP 133.2 mg & Valproic acid BP 58 mg equivalent to Sodium Valproate 200 mg.
300 tablet: Each enteric-coated controlled release tablet contains Sodium Valproate BP 199.8 mg & Valproic acid BP 87 mg equivalent to Sodium Valproate 300 mg.
500 tablet: Each enteric-coated controlled release tablet contains Sodium Valproate BP 333 mg & Valproic acid BP 145 mg equivalent to Sodium Valproate 500 mg.
Description:
Sodium Valproate & Valproic Acid, the active ingredient of Sodium Valproate & Valproic Acid is endowed with anti-epileptic activity against a variety of seizures. The mechanism by which Sodium Valproate exerts its anti-epileptic effects has not been established. However, it has been suggested that its activity is related to increased brain levels of gamma-aminobutyric acid (GABA).
Dosage & Administration:
Sodium Valproate & Valproic Acid is a prolonged-release formulation of sodium Valproate, thus Sodium Valproate & Valproic Acid may be given once or twice daily.
Epilepsy: Adults -Initially 600 mg daily given in 2 divided doses, preferably after food, increasing by 200 mg/day at 3-day intervals to a maximum of 2.5 g daily in divided doses until control of seizure is achieved. The usual maintenance dose is 1-2 g daily (20-30 mg/kg daily).
Children Initially 20 mg/kg daily in divided doses, may be increased (up to 20 kg) provided plasma concentrations monitored (above 40 mg/kg daily also monitor clinical chemistry and haematological parameters).
Children Initially 400 mg daily in divided doses increased until control (0ver 20 kg) (usually in the range of 20-30 mg/kg daily); Maximum 35 mg/kg daily.
Febrile convulsion20-30 mg/kg/day in 3 divided doses.
Bipolar disorder initially 20-30 mg/kg/day in 2-3 divided doses; adjust dosage in 3-5 days. The maintenance dosage is 1000-2000 mg/day. Prophylaxis of migraine 300 mg twice daily, although some may require 1000 mg daily.
Side Effects:
The most common side effects are anorexia, nausea and vomiting. However, these side effects are minimized with the use of enteric-coated tablets. Effects on the CNS include sedation, ataxia and tremor. These symptoms occur infrequently and usually respond to a decrease in doses. Rash, alopecia and stimulation of appetite have been observed occasionally. Sodium Valproate has several effects on the hepatic function of which elevation of liver enzymes in plasma is observed in up to 40% of patients and often occurs asymptomatically during the first few months of therapy. Rarely fulminate hepatitis that may be fatal may develop. Children below 2 years of age with other medical conditions and those being treated with multiple antiepileptic agents are especially prone to suffer from hepatic injury, acute pancreatitis and hyperammonemia have also been frequently associated with the use of Sodium Valproate.
Precautions:
Liver functions should be monitored before therapy and during the first 6 months especially in patients most at risk, No undue potential for bleeding before starting and before major surgery must be ensured, Care should be taken in renal impairment, pregnancy, breast-feeding and systemic lupus erythematosus. Sodium Valproate is partially eliminated in the urine as a ketone metabolite, which may lead to a false interpretation of the urine ketone test. Sudden withdrawal of therapy should be avoided.
Use in Pregnancy & Lactation:
Sodium Valproate crosses the placenta and in humans, exposure to valproate in the first trimester has been associated with neural tube defects such as anencephaly and spina bifida in newborn. Pregnant women treated with Sodium Valproate & Valproic Acid should be offered to estimate serum a-fetoprotein. Sodium Valproate & Valproic Acid is excreted in breast milk. However, breastfeeding by a mother taking Sodium Valproate & Valproic Acid probably causes no risk to the child.
Interaction:
Sodium Valproate appears to act as a non-specific inhibitor of drug metabolism. Drugs to which it interacts most significantly are Phenobarbital, Phenytoin, Warfarin, Aspirin etc.
Storage:
Store in a cool and dry place, below 30 °C and keep away from light.
0 Comments
if you have any doudts.please let me know